Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion

Secukinumab, an interleukin (IL)-17A antagonist, was associated with disease exacerbations in Crohn’s disease, and de novo cases of inflammatory bowel disease (IBD) have been reported in studies of rheumatoid diseases. However, there has been no detailed report demonstrating the linkage between secu...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :ACG Case Rep J
Главные авторы: Wang, Jingzhou, Bhatia, Arvin, Krugliak Cleveland, Noa, Gupta, Nina, Dalal, Sushila, Rubin, David T., Sakuraba, Atsushi
Формат: Artigo
Язык:Inglês
Опубликовано: American College of Gastroenterology 2018
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6072803/
https://ncbi.nlm.nih.gov/pubmed/30105273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14309/crj.2018.56
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы